Table 14.1.
A summary of vaccines for MERS in clinical development as of October 2021.
| Status | Description of trial | Intervention | Locations |
|---|---|---|---|
| Phase 1 Terminated (Oct 2021) | Safety and Immunogenicity of a candidate MERS-CoV vaccine (MERS001) | ChAdOx1 MERS | Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK |
| Phase 1 Completed (May 2019) | Safety, Tolerability, and Immunogenicity of Vaccine candidate MVA-MERS-S | Vaccine candidate MVA-MERS-S | CTC North GmbH & Co. KG, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany |
| Phase 1 Completed (Nov 2020) | A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002) | ChAdOx1 MERS | King Abdulaziz Medical City, National Guard Health Affairs Riyadh, Saudi Arabia |
| Phase 1 Recruiting | Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS | Biological: MVA-MERS-S_DF1 - Low Dose Biological: MVA-MERS-S_DF1 - High Dose Other: Placebo |
CTC North, Hamburg, Germany Erasmus Medical Center, Rotterdam, Netherlands |
| Phase 1 (vaccine) Phase 2 (other placebo). Recruiting | Study of Safety and Immunogenicity of BVRS-GamVac | Biological: BVRS-GamVac Other: Placebo |
Research Institute of Influenza, Sankt-Peterburg, Russian Federation |
| Phase 1 (vaccine) Phase 2 (other placebo). Recruiting | Study of Safety and Immunogenicity of BVRS-GamVac-Combi | Drug: BVRS-GamVac-Combi Other: Placebo |
ECO Safety Sankt-Peterburg, Russian Federation |
| Phase 1 (vaccine); Phase 2 (Electroporation). Completed Apr 2020 | Evaluate the Safety, Tolerability, and Immunogenicity Study of GLS-5300 in Healthy Volunteers | Biological: GLS-5300 Device: Cellectra 2000 Electroporation |
Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seoul National University Hospital, Seoul, Republic of Korea |
| Phase 1 Completed Sept 2017 | Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers | Biological: GLS-5300 | Walter Reed Institute of Research, Silver Spring, Maryland, United States |
Source: Adapted from data at www.clinicaltrials.gov. Accessed 25 October 2021.